صورة
Image1_Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.PDF
| العنوان: | Image1_Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients.PDF |
|---|---|
| المؤلفون: | Marina Camera, Paola Canzano, Marta Brambilla, G. Enrico Rovati |
| سنة النشر: | 2022 |
| المجموعة: | Frontiers: Figshare |
| مصطلحات موضوعية: | Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, COVID-19, leukotrienes, leukotriene antagonists, platelet activation, tissue factor, P-selectin |
| الوصف: | Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely LTC 4 , LTD 4 , and LTE 4 are involved in many of the principal features of asthma, while more recently they have also been implicated in cardiovascular diseases. COVID-19 is characterized by an overwhelming state of inflammation, sometimes resulting in an acute respiratory distress syndrome. Furthermore, severe COVID-19 patients present an endothelial cell damage characterized by a hyperinflammatory/procoagulant state and a widespread thrombotic disease. Leukotriene receptor antagonists, such as montelukast, have long been proven to have an efficacy in asthma, while more recently they have been suggested to have a protective role also in cardiovascular diseases. As elevated levels of LTE 4 have been detected in bronchoalveolar lavage of COVID-19 patients, and montelukast, in addition to its anti-inflammatory properties, has been suggested to have a protective role in cardiovascular diseases, we decided to investigate whether this drug could also affect the platelet activation characteristic of COVID-19 syndrome. In this contribution, we demonstrate that montelukast inhibits platelet activation induced by plasma from COVID-19 patients by preventing the surface expression of tissue factor (TF) and P-selectin, reducing the formation of circulating monocyte– and granulocyte–platelet aggregates, and, finally, in completely inhibiting the release of TF pos -circulating microvesicles. These data suggest the repurposing of montelukast as a possible auxiliary treatment for COVID-19 syndrome. |
| نوع الوثيقة: | still image |
| اللغة: | unknown |
| العلاقة: | https://figshare.com/articles/figure/Image1_Montelukast_Inhibits_Platelet_Activation_Induced_by_Plasma_From_COVID-19_Patients_PDF/19136195Test |
| DOI: | 10.3389/fphar.2022.784214.s001 |
| الإتاحة: | https://doi.org/10.3389/fphar.2022.784214.s001Test https://figshare.com/articles/figure/Image1_Montelukast_Inhibits_Platelet_Activation_Induced_by_Plasma_From_COVID-19_Patients_PDF/19136195Test |
| حقوق: | CC BY 4.0 |
| رقم الانضمام: | edsbas.6ADF8B1F |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fphar.2022.784214.s001 |
|---|